NCCN CNS tumor guidelines update for 2023
Neuro-Oncology · 08.12.2023 · 25 (12) · 2114-2116
DOI: 10.1093/neuonc/noad169 ↗Kurz gefasst
Editorial in der Zeitschrift Neuro-Oncology, online erschienen am 14.09.2023. Verfasst von Burt Nabors und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Neuro-oncology; Departments of Neurology and Neurosurgery, O'Neal Comprehensive Cancer Center, Heersink School o…. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, Division of Neuro-oncology; Departments of Neurology and Neurosurgery, O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
- Department of Medical Oncology and Research Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
- Moores Cancer Center, University of California San Diego, San Diego, California.
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
ORCID-Profile: Burt Nabors, Craig Horbinski
Zitieren
APA
Nabors, B., Portnow, J., Hattangadi-Gluth, J., & Horbinski, C. (2023). NCCN CNS tumor guidelines update for 2023. Neuro-Oncology, 25(12), 2114-2116. https://doi.org/10.1093/neuonc/noad169
Vancouver
Nabors B, Portnow J, Hattangadi-Gluth J, Horbinski C. NCCN CNS tumor guidelines update for 2023. Neuro-Oncology. 2023;25(12):2114-2116. doi:10.1093/neuonc/noad169
BibTeX
@article{Nabors2023,
author = {Nabors, Burt and Portnow, Jana and Hattangadi-Gluth, Jona and Horbinski, Craig},
title = {NCCN CNS tumor guidelines update for 2023},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {12},
pages = {2114--2116},
doi = {10.1093/neuonc/noad169}
}
EUVIMED